Successful primary engraftment of trem-cel in first five aml patients demonstrates promise of vor bio's platform

Cambridge, mass., june 09, 2023 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in vbp101, its phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly vor33) in patients with acute myeloid leukemia (aml). these data were presented by guenther koehne, md, phd, deputy director and chief of blood & marrow transplant and hematologic oncology at miami cancer institute of baptist health south florida in a poster presentation at the european hematology association (eha) 2023 congress in frankfurt, germany.
VOR Ratings Summary
VOR Quant Ranking